J9021 HCPCS Level II code: Injection, asparaginase, recombinant, (rylaze), 0.1 mg
J9021 is the HCPCS code for “Injection, asparaginase, recombinant, (rylaze), 0.1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J9021Injection, asparaginase, recombinant, (rylaze), 0.1 mg
Short description: Inj, aspara, rylaze, 0.1 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J9021 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care
- BETOS category
- Chemotherapy
- Added
- Jan 1, 2022
Where J9021 sits
- 1J codesDrugs administered other than orally
- 2Active code J9021Injection, asparaginase, recombinant, (rylaze), 0.1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J9021 mean?
J9021 is the HCPCS code for “Injection, asparaginase, recombinant, (rylaze), 0.1 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J9021?
CMS lists J9021’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J9021
All J codesJ9010Injection, alemtuzumab, 10 mgJ9011Injection, datopotamab deruxtecan-dlnk, 1 mgJ9015Injection, aldesleukin, per single use vialJ9017Injection, arsenic trioxide, 1 mgJ9019Injection, asparaginase (erwinaze), 1,000 iuJ9020Injection, asparaginase, not otherwise specified, 10,000 unitsJ9022Injection, atezolizumab, 10 mgJ9023Injection, avelumab, 10 mgJ9024Injection, atezolizumab, 5 mg and hyaluronidase-tqjsJ9025Injection, azacitidine, 1 mgJ9026Injection, tarlatamab-dlle, 1 mgJ9027Injection, clofarabine, 1 mg